Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C122680
http://purl.obolibrary.org/obo/NCIT_C122680
|
|---|---|
| Preferred Name | Ripertamab |
| Definitions |
A chimeric monoclonal antibody directed against human CD20, with potential antineoplastic activity. Ripertamab binds to the B-cell-specific cell surface antigen CD20, which triggers an immune response against CD20-positive B-cells, leading to apoptosis. CD20, a non-glycosylated cell surface phosphoprotein, is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A chimeric monoclonal antibody directed against human CD20, with potential antineoplastic activity. Ripertamab binds to the B-cell-specific cell surface antigen CD20, which triggers an immune response against CD20-positive B-cells, leading to apoptosis. CD20, a non-glycosylated cell surface phosphoprotein, is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. |
|---|---|
| prefLabel | Ripertamab
|
| label | Ripertamab
|
| PDQ_Closed_Trial_Search_ID | 772859
|
| code | C122680
|
| prefixIRI | NCIT:C122680
|
| in_subset | |
| Preferred_Name | Ripertamab
|
| FDA_UNII_Code | URS0374MIV
|
| Contributing_Source | FDA
|
| Maps_To | Anti-CD20 Monoclonal Antibody SCT400
|
| CAS_Registry | 2249927-04-4
|
| NCI_Drug_Dictionary_ID | 772859
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 772859
|
| Semantic_Type |
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C4053591
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |